Screener / SEC EDGAR /CIK 0000818686 /10-K filed Feb 3, 2026, compared with Feb 5, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Teva Pharmaceutical Industries Ltd TEVA

Compare with peers Embed
In the footnotes

What the 10-K filed Feb 3, 2026 says off the balance sheet

10-K notes
Topics with specifics 4 of 6 with a sentence that gives amounts, accruals or ratios
Sentences quoted 10 word for word, each linked to the 10-K
New this year 1 sentences with nothing like them in the 10-K filed Feb 5, 2025

Risks that are not on the face of the balance sheet. Tickdelta picks sentences with specifics and quotes them as filed. New marks a sentence with nothing like it in the 10-K filed Feb 5, 2025.

Big customers

Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).

No specific sentence about this in the 10-K.

Key suppliers

Parts or manufacturing that depend on one or a few suppliers.

“Department of Health and Human Services to set the prices of a subset of drugs and biologics with the highest annual expenditures under Medicare Parts B and D, which included AUSTEDO and AUSTEDO XR effective as of January 1, 2027, and in the future, could include other innovative products and biologics within our portfolio of products; and (iii) impose manufacturer rebates on certain single-source Part B and Part D drugs when prices rise faster than the rate of inflation.”

Read it in the 10-K

Lawsuits and legal claims

Pending cases, settlements and what the company has set aside for them.

1 new

“We recorded expenses of $467 million in legal settlements and loss contingencies in 2025, compared to expenses of $761 million in 2024.”

Read it in the 10-K

“In 2025, we recorded expenses of $467 million in legal settlements and loss contingencies, compared to expenses of $761 million in 2024.”

Read it in the 10-K

“Adjustments for legal settlements and loss contingencies in 2024 were mainly related to legal expenses of $357 million recorded in connection with a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision of $278 million for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore).”

Read it in the 10-K

New “Legal settlements and loss contingencies expenses in 2025 were $467 million, compared to expenses of $761 million in 2024 and expenses of $1,043 million in 2023.”

Read it in the 10-K

“As of December 31, 2025 and 2024, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,753 million and $4,881 million, respectively.”

Read it in the 10-K

Guarantees and indemnities

Promises to pay someone else's debts or losses if they cannot.

“In addition to the accounts receivables sold, as of December 31, 2025 and 2024, an amount of $799 million and $558 million of the SPV’s accounts receivables was pledged by the SPV as a seller guarantee, and is included under “Accounts receivables, net,” in the Consolidated Balance Sheet.”

Read it in the 10-K

Debt covenants

Conditions in loan agreements that, if broken, can make debt due early.

“The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time.”

Read it in the 10-K

“with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF.”

Read it in the 10-K

“Additionally, violations of the covenants, under the circumstances referred to above, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company’s senior notes and sustainability-linked senior notes due to cross-acceleration provisions.”

Read it in the 10-K

Commitments off the balance sheet

Contracts the company must pay for later: purchase obligations, take-or-pay deals.

No specific sentence about this in the 10-K.

Customers it names 0 tracked companies its filings call a customer
Suppliers it names 0 tracked companies its filings call a supplier
Companies that name it 0 tracked companies whose filings call it a customer or a supplier

Companies it names

Tracked companies that its latest 10-K or its 8-Ks of the last year call a customer or a supplier.

No other tracked company is named as a customer or a supplier in the latest filings.

Companies that name it

Tracked companies whose latest 10-K or 8-Ks call it a customer or a supplier.

No other tracked company names it as a customer or a supplier in the latest filings.

Sentences are chosen by their words, not read by AI, so some can be off topic. Always check the filing. Open the 10-K

Sources

The notes to the financial statements, Legal Proceedings and the MD&A of the latest 10-K (and, for customers and suppliers, Business and Risk Factors), quoted as filed.

Also

Debt: the debt note in numbers.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEVA/export.csv") into a cell.

Next:Reverse DCF
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.